Short-term (4-8 weeks) placebo-controlled trials are used to evaluate new antihypertensive drug treatment. To evaluate the consequences of such practice, a descriptive meta-analysis was conducted, consisting of blinded review of original case report forms for all patients who died or left a study before its completion for all short-term, placebo-controlled hypertension trials submitted to the Food and Drug Administration from 1973 through 2001. There were 93 marketing applications or supplements involving 590 individual trials that involved 86 137 randomized patients (64 438 randomized to experimental drug and 21 699 randomized to placebo) with 12 658 patient years of observation. There were 9636 dropouts (mean time to dropout was 28 days) and relative risk (RR (placebo/drug)) ¼ 1.33 (95% confidence limits, 1.28, 1.39; Po10
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). As expected, lack of blood pressure (BP) control was far more common in patients randomized to placebo; therapeutic failure, RR ¼ 2.53 (2.35, 2.73; Po10
À15
) and hypertensive emergency, RR ¼ 2.75 (2.19, 3.57; Po10
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Introduction
Long-term treatment of hypertension, even mild hypertension, protects patients from irreversible harm. [1] [2] [3] [4] [5] [6] [7] [8] [9] Approval of a new antihypertensive drug is primarily based upon short-term trials (usually 4-8 weeks), in which patients are randomly assigned to the new antihypertensive treatment or to a placebo, with blood pressure (BP) the principal end point. It has been presumed that such short-term exposures should not have adverse morbid/mortal consequences, but to date, there has been no formal analysis of all available data addressing that presumption.
Some data from long-term trials suggest that early lack of BP control might be harmful. 10 ,11 Yet, Al-Khatib et al. 12 -from a meta-analysis of published data from 25 placebo-controlled short-term trials (about 6409 patients and about 1602 patientyears of study)-concluded that harm associated with such assignments must be small or nonexistent. A much larger body of pertinent trial data is available to the US Food and Drug Administration, Division of Cardio-Renal Drug Products (FDA, DCRDP), in applications for marketing approval of new antihypertensive agents, combinations of drugs and new formulations of approved drugs. From all trial reports submitted to FDA between 1973 and 2001, the Division of CardioRenal Drug Products and collaborators reviewed the complete case report forms (CRFs) for each patient to describe the consequences of randomization to placebo. The patients were all those who withdrew (dropped out) for any reason from short-term antihypertensive trials (mean time to dropout was 28 days). The meta-analysis of these data is the Placebo in Hypertension Adverse Reaction Metaanalysis (PHARM) project.
Methods

Screening for relevant trials
From databases maintained by the FDA central administration and by the FDA's Division of Cardio-Renal Drug Products, we identified all new drug applications (NDAs) or NDA supplements (sNDAs) involving the treatment of hypertension. A supplement is an application that allows changes to a product that already has an approved NDA, such as a new indication. Only randomized, double blind and placebo-controlled trials were eligible for inclusion. Because these data had been submitted to FDA only for the purpose of regulatory approval, written permission to include all trials was obtained from each individual sponsor of each application.
Definition of dropout-classification criteria and combinations of primary events As listed in Table 1 , we predefined 13 categories to which patients withdrawing from trials were assigned.
Anticipating that individual events would be infrequent, in the original protocol, we identified three combinations of events of special interest; total serious events (death, angina pectoris, arrhythmia, congestive heart failure (CHF), cerebrovascular accident, cardiovascular accident (CVA), hypertensive emergency, myocardial infarction (MI) and transient ischaemic attacks (TIAs)), serious cardiovascular events, (angina, arrhythmia, CHF, MI), serious neurological events, (CVA, hypertensive emergency, TIA). Cardiovascular events other than the above were not included in any of those combinations.
Three retrospective analyses of combinations of events were performed. These were all dropouts excluding administrative and treatment failure but including hypertensive emergency, all dropouts excluding administrative and therapeutic failure (TF) and also excluding hypertensive emergency, and a combination of events that included only documented events of irreversible harm (death, MI, CVA). There were no end-stage renal disease events.
Review of case report forms
For each study, tabulation of the number of patients who die or leave a study prior to study termination because of an adverse event must be submitted in the NDA or sNDA. For each of these patients a complete set (each study visit as well as the terminating visit and usually a dropout form) of CRFs must also be provided in each application submitted to the FDA (exceptions can be allowed by prearrangement). If the patient drops out of the trial, the investigator is usually expected to indicate why, in his or her opinion, the patient was withdrawn.
We retrieved all (every study visit) CRFs for all reported dropouts (for any reason) from all of the trials included in our study (for crossover trials, we retrieved only the CRFs for the first period of the crossover, as the second period is hampered by carryover effects and other controversial aspects of this design). When CRFs were not present in the archived NDA or sNDA submission, duplicates were obtained from the drug sponsor. A team of health professionals then reviewed all of the CRFs of every patient who had dropped out of all trials. The reviewers were blinded to the patient assignment (placebo/drug).
From the CRFs, each of two reviewers (by patient and by study), separately generated a 62-field Excel spreadsheet record that included the patient's Events of VT were collapsed into AR in the final analysis.
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A DeFelice et al demographics, patient's BPs at baseline and at last routine visit, any adverse events observed and whether the dropout had been associated with admission to an emergency department or a hospital. The reviewers independently assigned the patient's primary reason (only one per patient) for withdrawal to one of the 13 categories listed in Table 1 . Reviewers were instructed that if two or more categories seemed equally applicable, the more serious category should be chosen as the primary reason. Some deference was given to the assessment that had been made by the investigator, but reviewers were free to assign a different category when it seemed to be more consistent with the other data in the CRFs, and/or in the definitions provided in the PHARM protocol. The reviewers' assessments were independently entered directly onto independent spreadsheets. The two reviewers' independent spreadsheets were then compared by ad hoc computer methods. Discrepancies of demography, vital signs and so on were resolved informally, but disagreements as to the primary reason for dropping out were referred to a 9-physician Dispute Resolution Executive Committee (DREC). In each of these cases, the patient's CRFs (with the patient's drug or placebo assignment still masked) were reviewed first by a 3-member subcommittee of FDA medical reviewers, and then, if consensus had not been reached, by the full Committee (nine FDA medical reviewers). After any discrepancies had been resolved as just described, ad hoc software was used to transcribe the spreadsheets into a form accessible to standard statistical software.
Statistical analysis
This is a descriptive, by patient (not by study) metaanalysis. Our primary target for estimation was the relative risk (RR, placebo/drug) of dropout for any cause, comparing the patients assigned to placebo to those assigned to active treatment (drug). For RR, P-values were determined and are reported without correction for multiple comparisons. If a Bonferroni correction is applicable ( Table 2 has 22 comparisons), for the sake of framework, a P-value equivalent to a standard P of 0.05 would require an uncorrected P of about 2 Â 10 À3 , and that of a standard P of 0.01 would require an uncorrected P of about 4 Â 10 À4 . We anticipated that most events of importance would be of low incidence, and would not occur at all in many of the included trials. Assumption of an asymptotic normal model might then have led to meaningless confidence intervals and other anomalies, 13 so our primary methodology was the maximum-likelihood method stratified by protocol. 13, 14 For completeness, we also used the conventional methods of Mantel and Haenszel 15, 16 (and found almost identical results compared to the maximumlikelihood method, Supplementary Information is available at Journal of Human Hypertension's website). After analysis of individual events, we conducted several analyses that aggregated events in some combination, including those prospectively defined in the protocol, but also three others as described above.
Absolute event rates were calculated as (no. of events/(patient years)) Â 1000 for each group and the 95% confidence intervals for the difference in rates (placebo/drug) were calculated assuming a constant risk across protocols and time of observation; maximum likelihood was not used for these calculations.
Other aggregate statistics were evaluated using paired comparisons and one-way analysis of variance; standard descriptive statistics were used as appropriate. Except for the ad hoc spreadsheet software noted above, we used standard software packages, including SAS and JMP (SAS Institute, Cary, NC, USA), Access (Microsoft Corporation, Redmond, WA, USA), R (http://cran.r-project.org) and S-Plus (Insightful Software, Seattle, WA, USA).
Establishment of context
We compared our findings from the short-term trials reported in FDA applications to the findings of longterm trials reported in the medical literature and plan to report this complicated comparison separately. Briefly, despite the fact that PHARM evaluated only short-term trials (weeks), the absolute risk of events (events per 1000 patient years) observed in PHARM fell well within the range of the absolute event rates in long-term trials, [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] for patients within the chronological age and magnitude of systolic BP defined by the PHARM population baseline values. For example, the total all cause mortality rate in PHARM was 3.4 per 1000 patient years, only slightly less than that reported by the CDC Division of Vital Statistics 30 for the year 2003 for this age group in the general population of the United States and total stroke events in PHARM was 3.1 per 1000 patient years, slightly greater than that seen in the MRC trial 20 and the Australian trial 19 in hypertensive populations.
Results
Eligible trials
Review of the FDA databases found 590 trials from a total of 93 different applications that met our inclusion criteria. There were 86 137 patients randomized in the trials, (64 438 assigned to active treatment, 21 699 to placebo, with 12 658 patientyears of observation time). Forty-two different chemical entities were represented, including a-1 antagonists, a-2 agonists, angiotensin-receptor blockers, angiotensin-converting-enzyme inhibitors (one with neutral endopeptidase inhibition), b-adrenergic blockers, calcium-channel blockers and diuretics. Abbreviations: AP, angina pectoris, AR, arrhythmia; CHF, congestive heart failure; CVA, cardiovascular accident; ER, emergency room; HOSP, hospital; HE, hypertensive emergency; MI, myocardial infarction; N, the number of patients randomized to each group; OAE, other adverse events; OC, other cardiac; OT, administrative; pt, patient; RR, relative risk; TIA, transient ischaemic attack; VT, ventricular tachycardia; yrs, the number of patient years in each group. The number of each recorded event, the event rate of the each event normalized to per 1000 patient years of follow-up, and the relative risk (RR, placebo/drug; a RR41.0 favours being randomized to drug treatment and o1.0 favours placebo treatment), both RR risk and P-value were estimated by the profile likelihood method, stratified by study. The D of event rates per 1000 patient years is the difference (placebo/drug) in event rates; positive D point estimates favour being randomized to drug treatment and negative point estimates favour being randomized to placebo treatment. Table 2 and Figure 1 (a representation of the RR data, which was the primary analysis and the only one with P-values), and Figure 2 (a representation of absolute rate data) the overall dropout rate was 949 dropouts per 1000 patientyears among patients randomized to placebo and 697 dropouts per 1000 patient-years among patients randomized to active treatment (RR ¼ 1.33, Po10 À16 ). For all dropouts, the difference of 251 per 1000 patient years excess in the placebo group was mainly driven by the 246 per 1000 patient years Figure 1 The figure is a plot of the relative risk (RR; x axis is on a log scale) of dropping out for all events and combination of events shown in Table 2 . The centre of each circle is the RR point estimate; the area of the circle is proportional to the number of events in the category (the largest circle being all dropouts, total events ¼ 9636 events). As in Table 2 , individual events and combinations of events are shown in decreasing total event order. Tips of arrows are at the 95% confidence limits for the estimation. Those items that are statistically significant are shown bolded, in comparison to those items that are not statistically significant. See, Methods section/definition of dropout-classification criteria and combinations of primary events for description of these combinations of events. For combinations of events, * ¼ prospectively defined of interest in the protocol.
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A DeFelice et al excess in TF. In the placebo group, there was also an excess of hypertensive emergency, discussed further below. With respect to major events (for example, stroke, MI, CHF and death), there were neither significant differences nor strong trends.
Some additional description of selected individual event categories and combined event analyses is as follows.
Administrative. The most frequent reason for dropping out was administrative, and this was slightly more common in the placebo group (RR, 1.09; P ¼ 0.031, uncorrected, see Statistical analysis section). In total 4% of this population were seen in the emergency rooms (ERs) or were hospitalized (7.8% placebo and 2.2% drug); interestingly, an incidence 4 times greater than that for TF. The reasons for dropout in this category were protocol deviations, loss to follow up, withdrawal of consent, non-compliance with dosing or scheduled study visits, relocation, transportation impediments, intercurrent illness, non-cardiovascular surgery or emergent physical limitations from accidents and so on.
Other adverse events. This was the second most frequent event type (2734 events, 28% of all Figure 2 This figure is a plot of the difference in absolute rate (placebo/drug) of dropping out for each category shown in Table 2 . Plot a (inset) shows only all dropouts (All), therapeutic failure (TF) and hypertensive emergency (HE), as the x-axis scale needs to include close to 300. Plot b shows the remainder (except that administrative dropouts (OT) are not plotted) on a different x axis scale. The centre of each circle is the D point estimate shown in Table 2 ; the area of the circle is proportional to the number of events in the category (the largest circle being all dropouts, total events ¼ 9636 events in plot a; the largest circle in plot b is other adverse events (OAE), total events ¼ 2734). Tips of arrows are at the 95% confidence limits for the estimation. Those items that are statistically significant (for relative risk, RR) are shown bolded, in comparison to those items that are not statistically significant. See, Methods section/definition of dropout-classification criteria and combinations of primary events for description of these combinations of events. For combinations of events, * ¼ prospectively defined of interest in the protocol.
A DeFelice et al dropouts) and was more common on drug. Although an expected outcome, the RR of 0.87 was only of borderline significance (P ¼ 0.0017). Most patients in this category had three or more different descriptive events recorded. For example, in a sample of the first 300 patients in this category, headache was most common, and in decreasing order were asthenia and lethargy, dizziness, laboratory abnormalities, skin rash, drowsiness, sexual dysfunction and others. There were 222 emergency-department/ hospital visits, but with equal frequency between drug and placebo groups (8% placebo, 8% drug), less than that associated with other cardiac causes (13% placebo, 11% drug) and greater than that of administrative.
Therapeutic failure. As expected, TF was much more common in the patients assigned to placebo (RR ¼ 2.53, Po10 À15 ). Most patients had some kind of symptom (for example, headache, nausea, vomiting and so on) in addition to lack of BP control. At the time of their last visit, this group had mean BPs of 166/108 and 172/109 mm Hg for systolic/diastolic, sitting and supine, respectively, representing a mean increase, compared to baseline, of 6 and 4 mm Hg, systolic and diastolic, respectively. Very few of these patients were seen in an emergency department (12 patients, 0.4%) or admitted to a hospital (10 patients, 0.4%) in association with their study withdrawal.
Cardiac adverse events. In total, 90% of the 469 patients with cardiac adverse events had a single descriptive event, and 10% had more than one event (for example, hypotension and dizziness) and was much more common on drug (RR, 0.33; Po10 À15 ). These events were, in decreasing order, postural hypotension (8 placebo, 156 drug), bradycardia and/or palpitations (8 placebo, 88 drug), hypotension (4 placebo, 67 drug), angio-oedema (1 placebo, 57 drug), non-descript electrocardiogram changes and/or ischaemia and non-descript chest pain (14 placebo, 43 drug), pitting oedema of extremities (6 placebo, 38 drug), dizziness (1 placebo, 17 drug), syncope (1 placebo, 17 drug) and fatigue and shortness of breath (5 placebo, 9 drug). There were 54 (13%) unscheduled visits in this population (25 placebo, 29 drug). Of the 54 unscheduled visits, 27 (50%) were due to hypotension/postural hypotension and 10 (19%) were due to angiooedema.
Hypertensive emergency. As a priori defined, hypertensive emergency (HE) was much more common in the placebo group (RR ¼ 2.75; Po10 À15 ), a RR almost identical to that of TF, and hypertensive emergency contributed 26 (per 1000 patient years) excess dropouts in the placebo group. The HE category was originally intended to only include patients who had signs or symptoms of endorgan damage, but we also predefined an absolute diastolic BP (DBP) or change of DBP. The protocolspecified absolute BP criterion for HE (DBP4110 mm Hg), a strictly enforced rule during adjudication, was already satisfied at baseline by about 10% of all PHARM patients. Similar to patients assigned to the TF category, patients assigned to hypertensive emergency had one or another symptom, but even if the symptoms were headache, non-anginal chest pain, erectile dysfunction, rashes, flu-like syndromes and so on, yet if the DBP was greater than 110 mm Hg, the patient was placed in the HE category rather than TF. Only 17 patients (out of the 279 in the HE category) were declared as hypertensive emergencies by the principal investigator of the trial; the other 262 patients were placed in this category only because of the authors' deliberations. Our prospective intent to qualitatively distinguish between TF and hypertensive emergency failed, so that the category of hypertensive emergency in this study is misleading.
On the other had, at the time of their last regular study visit, the hypertensive emergency group had mean BPs of 182/118 and 190/119 mm Hg for systolic/diastolic, sitting and supine, respectively, representing a mean increase, compared to baseline of 17 and 12 mm Hg, systolic and diastolic, respectively; both being appreciably greater than that for the patients considered TF. In addition, 37 of the 279 patients in this category did have clinical findings, such as retinopathy, neurological findings not quite qualifying as TIA or CVA (or they would have been placed in serious neurological events), internal carotid dissection and other findings of similar severity.
Although the point estimate for the RR of hypertensive emergency is a reliable estimate (almost identical to that of TF), the point estimate of 26 per 1000 patient years excess dropouts in the placebo group is in our opinion an inflated number and of unreliable magnitude (the PHARM incidence being at least an order of magnitude greater than most longterm intervention trials report). Around the time of their withdrawal, 26 of the hypertensive emergency group (7.5% placebo, 11.0% drug) were seen in an emergency department and another 26 were hospitalized (9.0% placebo, 9.7% drug). Unscheduled visits were more frequent in the hypertensive emergency group than the rate of 0.8% in the TF category, but the signs and/or symptoms appeared reversible, and there was no irreversible harm observed in the hypertensive emergency group.
Arrhythmia. There were only 90 (17 placebo, 73 drug) such events, and the RR of 0.64 was not statistically significant, but they are noted here because 43% of the arrhythmia group was hospitalized or had an ER visit related to the event. The most frequent (58) of these events was atrial dysrhythmia (13 placebo, 39 drug) and 35 (39% if all arrhythmias) of these were atrial fibrillation/ flutter (10 placebo, 59% of the arrhythmia population, 25 drug, 34% of the arrhythmia population).
Combinations of events of interest. As shown in Table 2 , serious cardiovascular events (angina, arrhythmia, CHF or MI) were about equally common in the drug and placebo groups, and the same is true of the irreversible-harm group (death, stroke or myocardial infarction), but there were few events in either group, and the confidence limits for these estimates were fairly wide (for example, for serious cardiovascular events the 95% confidence limits for RR were 0.76-1.29; for irreversible harm, 0.71-1.47). It is worth noting that eliminating dropouts for administrative reasons, TF or hypertensive emergency gave a RR of 0.80 (Po10 À8 ), favouring being randomized to the placebo group.
Discussion
As expected, there were few individual major clinical events, resulting in point estimates with rather wide confidence limits, and confidence limits remained wide even for combined events. For example, the RR for irreversible harm was 1.03 (a 3% excess risk), if randomized to placebo, but confidence intervals ranged from a 29% decreased risk (drug benefit) to 47% increased risk (placebo harm). The irreversible harm point estimate of an absolute incidence of 1.4 excess events per 1000 patient years places this in the rare category and each of its components (death, MI and CVA) even rarer in absolute incidence.
Of the six combined event analyses that were conducted, there were only two that suggest being randomized to placebo is harmful. Both of these two, contained events identified as hypertensive emergency, a category that, as noted above, had a faulty prospective definition and confound PHARM's interpretation. For hypertensive emergency, the absolute rate of 26.2 per 1000 patient years point estimate (Table 2 and Figure 2 ), excess if randomized to placebo, is almost identical to the excess for total serious events and serious neurological events (28.1 and 27.1, respectively). All four other point estimates of absolute rates are either neutral or favour being randomized to placebo.
We think the most appropriate descriptor of the PHARM combined events is all events absent administrative, TF and hypertensive emergency. The RR ¼ 0.80 (0.74, 0.86, Po10 À8 ) for this aforementioned category rather strongly favours being randomized to placebo. There were 3626 such events (2810 placebo, 816 drug) with an excess of 45 per thousand patient years in the group randomized to drug. Even if the inflated absolute risk of hypertensive emergency is included, the result still favours being randomized to placebo, although less compellingly. These observations, along with the lack of obvious evidence for causing irreversible harm, suggest that the continued use of placebo in short-term antihypertensive is reasonably safe.
For the group of patients that had irreversible harm (CVA, MI and death), lack of BP control was not obviously related to the events, as reflected by interim visit BPs and the last routine visit BPs. For the entire irreversible harm group, compared to baseline, there was a decrease in BP during the trials; the group median difference was À12 mm Hg systolic and À9 Hg diastolic for supine BP. In each individual event group there was a somewhat greater decrease in BP for patients randomized to drug, but there was a decrease in median BPs in each individual event category (with both placebo and drug), except for CVA where the median BPs increased a couple of mm Hg (in both placebo and drug groups). Further, antihypertensive therapy had no appreciable treatment benefit, and when irreversible harm events did occur there was no obvious relationship to lack of BP control. These observations do not argue against the desirability of longterm (months and years) BP control, as that is well established from both observational and placebocontrolled randomized clinical trial data. However, whether there is a long-term consequence of shortterm (weeks) lack of BP could not be analysed in our study, and may deserve systematic evaluation. We are aware of only two small, placebo-controlled trials, 31, 32 designed to evaluate very short-term (days) BP control in patients with very high baseline BPs, neither of which measured clinical end points. From those studies as well as others, 33, 34 it appears that rapid control of BP could be more harmful than beneficial, but a definitive conclusion is not possible.
PHARM is the largest meta-analysis of short-term placebo-controlled antihypertensive trials yet reported, and randomization to placebo was not associated with detectable irreversible harm, despite a total of 160 events. It is unlikely that in the foreseeable future that a larger database will either be available or be analysed. From the PHARM analysis, although there are clear risks associated with participation in a short-term antihypertensive trial (some for drug, others for placebo), there is no objective reason to conclude that the use of placebo in short-term antihypertensive trails need be discouraged.
Limitations
Publication bias, a problem for most meta-analyses, is essentially non-existent in the PHARM study; all original CRFs for each patient were reviewed from every study submitted in support of an NDA or sNDA (whether approved or not). Studies performed under an Investigational New Drug (IND), however, that never progressed to submission of an NDA or supplement is not part of the PHARM database (there might be a few, but we are aware of only one, Placebo in antihypertensive trialsmoxonidine). Also, PHARM has no information with respect to the placebo run-in phase of any study and has no information with respect to events after the studies were concluded.
Additionally, ascertainment bias did occur. We are aware of four errors in classification out of the 9636 events recorded (but we did not correct for the known four errors of classification in this report). Finally, and in retrospect, our definition of hypertensive emergency (the inclusion of absolute BP in the definition) was a significant flaw in our prospectively defined classification.
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